Royalty Pharma Q3 2021 Earnings Report
Key Takeaways
Royalty Pharma reported a 9% increase in total income and other revenues to $586 million, driven by strong portfolio performance, new royalty acquisitions, and a one-time payment related to Soliqua. Adjusted Cash Receipts increased 24% to $587 million, and Adjusted Cash Flow grew 12% to $441 million.
Net cash provided from operating activities (GAAP) was $470 million.
Adjusted Cash Receipts (non-GAAP) increased 24% to $587 million.
Adjusted Cash Flow (non-GAAP) grew 12% to $441 million.
2021 Adjusted Cash Receipts guidance raised to $2,110 to $2,130 million.
Royalty Pharma
Royalty Pharma
Forward Guidance
Royalty Pharma anticipates 2021 Adjusted Cash Receipts to be between $2,110 million and $2,130 million, excluding new transactions announced after the date of this release. Payments for operating and professional costs will be approximately 9% of Adjusted Cash Receipts in 2021.